Version 1.0 — Published March 2026
Quick Answer
The single costliest biochemistry mistake in NEET PG is confusing the rate-limiting enzymes across metabolic pathways — because this concept reappears in Medicine questions on diabetes pathogenesis, lactic acidosis, statin mechanism, and inborn errors of metabolism. To protect your 10-15 biochemistry marks and the 10+ downstream Medicine and Pharmacology marks:
- Memorize rate-limiting enzymes with their regulation — PFK-1 for glycolysis (not hexokinase), isocitrate dehydrogenase for TCA, HMG-CoA reductase for cholesterol (the statin target), CPT-1 for fatty acid oxidation (inhibited by malonyl-CoA), CPS-I for urea cycle
- Distinguish competitive from non-competitive inhibition on Lineweaver-Burk — competitive = same Vmax, increased Km; non-competitive = decreased Vmax, same Km
- Memorize purely ketogenic amino acids — only leucine and lysine (the two Ls); phenylalanine and tyrosine are both ketogenic AND glucogenic, NOT purely ketogenic
Why biochemistry mistakes are costly
Biochemistry contributes 10-15 questions to NEET PG (2021-2024 pattern analysis), and while that is fewer than Medicine or Pharmacology, biochemistry errors cascade into Medicine (diabetes, lactic acidosis, liver function interpretation), Pharmacology (drug metabolism via CYP450, statin mechanism, methotrexate), Pathology (hemoglobinopathies, tumor markers), and PSM (nutritional deficiencies in Indian populations). A candidate who confuses PFK-1 with hexokinase as the glycolysis rate-limiting step will also get wrong answers on diabetic ketoacidosis pathogenesis, on fructose-2,6-bisphosphate regulation, and on exercise biochemistry. The biochemistry deficit propagates — the real mark loss is 20-25 across papers, not just 10-15 within biochemistry.
Unlike Medicine which rewards disease-pattern recognition, biochemistry rewards mechanistic reasoning — "given this enzyme defect, which metabolite accumulates and which is deficient?" Students who memorize enzyme names without pathway positions lose the biochemistry questions AND the clinical integrations. The ten mistakes below are the patterns that consistently appear in wrong-answer analyses across AIIMS, PGI, and private coaching mock papers. Each mistake includes what students typically do, why it fails, the correct approach, and an example MCQ demonstrating the trap.
For comprehensive biochemistry strategy, pair this guide with the NEET PG biochemistry high-yield topics and the cross-subject common physiology mistakes guide.
Mistake 1: Confusing enzyme kinetics (Km, Vmax, competitive vs non-competitive inhibition)
What students do: Mix up Km and Vmax effects of competitive and non-competitive inhibitors; invert the Lineweaver-Burk plot interpretation.
Why it is wrong: Enzyme kinetics MCQs test Km/Vmax changes, Lineweaver-Burk line convergence, and clinical examples (methotrexate, allopurinol, fomepizole). Getting the kinetics wrong changes every downstream pharmacology answer.
Correct approach: Memorize the kinetics table with Lineweaver-Burk signatures.
| Parameter | No inhibitor | Competitive inhibitor | Non-competitive inhibitor | Uncompetitive inhibitor |
|---|
| Vmax | Baseline | UNCHANGED | DECREASED | DECREASED |
| Km | Baseline | INCREASED (apparent) | UNCHANGED | DECREASED |
| Lineweaver-Burk y-intercept (1/Vmax) | Baseline | Same y-intercept | Different y-intercept (higher) | Different y-intercept (higher) |
| Lineweaver-Burk x-intercept (-1/Km) | Baseline | Different x-intercept (closer to 0) | Same x-intercept | Different x-intercept (further from 0) |
| Overcome by more substrate? | — | YES | NO | NO |
| Classic drug example | — | Methotrexate vs DHFR; allopurinol vs xanthine oxidase; fomepizole vs alcohol dehydrogenase | Cyanide vs cytochrome oxidase (covalent); heavy metals | Rare clinically (lithium on inositol monophosphatase) |
Mnemonic: "Competitive competes, can be out-competed → same Vmax. Non-competitive knocks enzyme out → lower Vmax."
Example MCQ:
A drug inhibits dihydrofolate reductase (DHFR). Kinetic analysis shows that adding the drug increases the apparent Km but does NOT change Vmax. The inhibition is best described as:
- (a) Competitive inhibition
- (b) Non-competitive inhibition
- (c) Uncompetitive inhibition
- (d) Irreversible inhibition
Answer: (a). Competitive inhibition shows UNCHANGED Vmax (can be overcome with more substrate) and INCREASED Km (apparent — you need more substrate to reach half-max velocity). Methotrexate is a classic competitive DHFR inhibitor. Non-competitive would DECREASE Vmax with UNCHANGED Km.
Mistake 2: Mixing up glycolysis regulatory enzymes (PFK-1 is rate-limiting, not hexokinase)
What students do: Call hexokinase the "rate-limiting" enzyme of glycolysis because it is the first step.
Why it is wrong: Rate-limiting is NOT the same as "first step." Hexokinase is the first step but PFK-1 is the committed, allosterically regulated, rate-limiting step. Getting this wrong costs marks on diabetes pathogenesis, exercise biochemistry, and fructose-2,6-bisphosphate regulation.
Correct approach: Memorize rate-limiting enzymes with their regulators.
| Pathway | Rate-limiting enzyme | Activators | Inhibitors |
|---|
| Glycolysis | Phosphofructokinase-1 (PFK-1) | AMP, fructose-2,6-bisphosphate (F-2,6-BP), insulin | ATP, citrate, glucagon |
| Gluconeogenesis | Fructose-1,6-bisphosphatase-2 (FBP-2) | Citrate, glucagon | AMP, F-2,6-BP, insulin |
| TCA cycle | Isocitrate dehydrogenase | ADP, Ca2+ | ATP, NADH |
| Fatty acid synthesis | Acetyl-CoA carboxylase | Citrate, insulin | Palmitoyl-CoA, glucagon, AMP-activated protein kinase |
| Fatty acid oxidation | Carnitine palmitoyltransferase-I (CPT-I) | — | Malonyl-CoA (couples to fatty acid synthesis — cannot oxidize and synthesize simultaneously) |
| Cholesterol synthesis | HMG-CoA reductase | Insulin, thyroxine | Glucagon, cholesterol, statins |
| Ketogenesis | HMG-CoA synthase (mitochondrial) | Acetyl-CoA excess | — |
| Urea cycle | Carbamoyl phosphate synthetase-I (CPS-I) | N-acetylglutamate | — |
| Pyrimidine synthesis | Aspartate transcarbamoylase (prokaryotes); CPS-II (eukaryotes) | — | UTP, CTP feedback |
| Purine synthesis | Glutamine-PRPP amidotransferase | PRPP | AMP, GMP, IMP feedback |
| Heme synthesis | ALA synthase | — | Heme feedback; inhibited in lead poisoning (ALA dehydratase blocked) |
| Glycogen synthesis | Glycogen synthase | Insulin, glucose-6-phosphate | Glucagon, epinephrine |
| Glycogenolysis | Glycogen phosphorylase | Glucagon, epinephrine, AMP | ATP, glucose-6-phosphate, insulin |
Example MCQ:
Fructose-2,6-bisphosphate is a potent activator of which enzyme in the fed state?
- (a) Hexokinase
- (b) Phosphofructokinase-1 (PFK-1)
- (c) Pyruvate kinase
- (d) Phosphofructokinase-2 (PFK-2)
Answer: (b). F-2,6-BP is the most potent allosteric activator of PFK-1 (the rate-limiting step of glycolysis). It simultaneously inhibits FBP-2 (rate-limiting step of gluconeogenesis). F-2,6-BP is synthesized by PFK-2 (a bifunctional enzyme with both kinase and phosphatase activity); insulin promotes its formation by dephosphorylating the bifunctional enzyme. This is how insulin stimulates glycolysis and inhibits gluconeogenesis simultaneously.
Mistake 3: Confusing ketogenic vs glucogenic amino acids (only leucine and lysine purely ketogenic)
What students do: List phenylalanine and tyrosine as "purely ketogenic" or list too many amino acids as ketogenic.
Why it is wrong: NEET PG tests the exact list. Only TWO amino acids are purely ketogenic (leucine and lysine); five are BOTH (isoleucine, phenylalanine, threonine, tryptophan, tyrosine); thirteen are purely glucogenic.
Correct approach: Memorize the three categories.
| Category | Amino acids | Metabolic fate |
|---|
| Purely ketogenic (the two Ls) | Leucine, Lysine | Converted to acetyl-CoA or acetoacetate only; cannot form glucose |
| Both ketogenic AND glucogenic | Isoleucine, Phenylalanine, Threonine, Tryptophan, Tyrosine | Can form both ketone bodies and glucose |
| Purely glucogenic (remaining 13) | Alanine, Arginine, Asparagine, Aspartate, Cysteine, Glutamate, Glutamine, Glycine, Histidine, Methionine, Proline, Serine, Valine | Enter gluconeogenesis via pyruvate, OAA, alpha-KG, succinyl-CoA, or fumarate |
Mnemonic: "I'M PTT" for both-ketogenic-and-glucogenic (Isoleucine, Phenylalanine, Threonine, Tryptophan, Tyrosine — note the repeated T pattern in the last three).
Example MCQ:
Which of the following amino acids is PURELY ketogenic?
- (a) Phenylalanine
- (b) Tyrosine
- (c) Leucine
- (d) Isoleucine
Answer: (c). Leucine and lysine are the only two purely ketogenic amino acids. Phenylalanine, tyrosine, isoleucine, threonine, and tryptophan are BOTH ketogenic and glucogenic (they yield both acetyl-CoA/acetoacetate AND glucose precursors depending on metabolism). All others are purely glucogenic.
Mistake 4: Wrong urea cycle disorders (OTC is X-linked; orotic aciduria is pyrimidine synthesis defect)
What students do: Confuse OTC deficiency (urea cycle, hyperammonemia, orotic aciduria, X-linked) with orotic aciduria (pyrimidine synthesis defect, megaloblastic anemia, NORMAL ammonia, autosomal recessive).
Why it is wrong: Both conditions have high urinary orotic acid. The differentiators are ammonia level and the metabolic category.
Correct approach: Distinguish by ammonia, citrulline, inheritance, and clinical presentation.
| Feature | OTC deficiency | Orotic aciduria (UMP synthase def.) | CPS-I deficiency | Citrullinemia (ASS deficiency) |
|---|
| Pathway | Urea cycle | Pyrimidine synthesis | Urea cycle (rate-limiting step) | Urea cycle |
| Inheritance | X-linked (only X-linked urea cycle disorder) | Autosomal recessive | Autosomal recessive | Autosomal recessive |
| Ammonia | HIGH (hyperammonemia) | NORMAL | HIGH (severe) | HIGH |
| Citrulline | LOW (OTC makes citrulline) | Normal | LOW | HIGH (cannot be used downstream) |
| Urinary orotic acid | HIGH (carbamoyl phosphate spills into pyrimidine synthesis) | HIGH (UMP synthase cannot convert orotate to UMP) | NORMAL | NORMAL |
| Key clinical feature | Hyperammonemic encephalopathy in males; milder in heterozygous females | Megaloblastic anemia, failure to thrive, no hyperammonemia | Severe hyperammonemia in newborns | Hyperammonemia in newborns |
| Treatment | Low-protein diet + ammonia scavengers (sodium benzoate, phenylbutyrate); liver transplant curative | Uridine supplementation | Low-protein diet + ammonia scavengers | Low-protein diet + arginine |
Example MCQ:
A 2-day-old male newborn presents with lethargy, poor feeding, seizures, and coma. Labs show blood ammonia 500 micromol/L (markedly raised), plasma citrulline low, and urinary orotic acid HIGH. The most likely diagnosis is:
- (a) Ornithine transcarbamylase (OTC) deficiency
- (b) Orotic aciduria (UMP synthase deficiency)
- (c) Carbamoyl phosphate synthetase-I (CPS-I) deficiency
- (d) Phenylketonuria (PKU)
Answer: (a). OTC deficiency is the only urea cycle disorder that combines HIGH ammonia, LOW citrulline, AND HIGH urinary orotic acid. Inheritance is X-linked — male newborn presentation is classic. Orotic aciduria would show normal ammonia (pyrimidine defect, not urea cycle). CPS-I deficiency would show low citrulline and high ammonia but NORMAL orotic acid (carbamoyl phosphate substrate does not accumulate because CPS-I is defective). PKU presents later with developmental delay, eczema, and a musty body odor — not hyperammonemia.
Mistake 5: Mixing up vitamin deficiencies by system (B1 beriberi, B12 SCD, niacin pellagra, C scurvy, K clotting)
What students do: Swap B12 neurological features with folate; attribute pellagra's 4 Ds to B12 instead of niacin.
Why it is wrong: Vitamin deficiency MCQs are high-yield and integrate with Medicine (anemias), Neurology (SCD), Dermatology (pellagra, scurvy), and PSM (nutrition programs).
Correct approach: Match vitamin → deficiency disease → signature clinical feature.
| Vitamin | Deficiency disease | Key clinical features | Classic test / pearl |
|---|
| A (retinol) | Xerophthalmia, keratomalacia | Night blindness (early), Bitot spots, corneal ulceration | WHO/UNICEF child supplementation; overdose causes pseudotumor cerebri |
| B1 (thiamine) | Beriberi, Wernicke-Korsakoff | Dry beriberi (neuropathy); wet beriberi (high-output heart failure); Wernicke triad (confusion + ophthalmoplegia + ataxia); Korsakoff psychosis | ALCOHOLICS at risk; always give thiamine BEFORE glucose in suspected alcoholics |
| B2 (riboflavin) | Ariboflavinosis | Angular cheilitis, glossitis, seborrheic dermatitis, corneal vascularization | FAD and FMN coenzyme precursor |
| B3 (niacin) | Pellagra | 4 Ds: Dermatitis (photosensitive, sun-exposed areas, Casal necklace), Diarrhea, Dementia, Death | Corn-based diet; Hartnup disease; carcinoid syndrome depletes tryptophan |
| B5 (pantothenic acid) | Rare; burning feet syndrome | CoA precursor | — |
| B6 (pyridoxine) | Peripheral neuropathy, sideroblastic anemia, seizures (infants) | INH-induced neuropathy; give B6 with INH prophylactically | PLP coenzyme for transaminases |
| B7 (biotin) | Rare; dermatitis, alopecia | Raw egg white (avidin) binds biotin — don't eat raw eggs long-term | Carboxylation coenzyme |
| B9 (folate) | Megaloblastic anemia WITHOUT neurological features | Neural tube defects in pregnancy; preconception supplementation; methotrexate inhibits DHFR | MCV raised, hypersegmented neutrophils |
| B12 (cobalamin) | Megaloblastic anemia WITH neurological features | Subacute combined degeneration (posterior columns + lateral corticospinal tract); glossitis | Schilling test (historical); pernicious anemia (anti-IF antibodies) |
| C (ascorbate) | Scurvy | Bleeding gums, perifollicular hemorrhages, corkscrew hairs, poor wound healing | Collagen hydroxylation defect; also increases iron absorption |
| D (cholecalciferol) | Rickets (children), osteomalacia (adults) | Bow legs, rachitic rosary, craniotabes, Harrison sulcus; low Ca, low PO4, high ALP, high PTH | Sun exposure and dietary intake; active form 1,25-(OH)2-D made in kidney |
Key distinctions:
- B12 vs folate: both cause megaloblastic anemia; only B12 causes neurological features (SCD)
- Pellagra's 4 Ds = niacin (B3), not B12
- Wernicke triad = thiamine (B1), not B12 (unless combined deficiency in alcoholics)
- Scurvy = vitamin C (collagen); bruising with normal platelets and clotting screen
Example MCQ:
A 68-year-old chronic alcoholic man presents with confusion, horizontal gaze paralysis (ophthalmoplegia), and wide-based gait ataxia. Labs show macrocytic anemia. Which vitamin should be administered IMMEDIATELY, BEFORE giving IV dextrose?
- (a) Vitamin B12 (cobalamin)
- (b) Folate
- (c) Vitamin B1 (thiamine)
- (d) Vitamin C (ascorbate)
Answer: (c). The classic Wernicke triad (confusion + ophthalmoplegia + ataxia) is thiamine deficiency. In alcoholics, giving IV dextrose without thiamine can precipitate or worsen Wernicke encephalopathy because glucose utilization consumes remaining thiamine stores. ALWAYS give thiamine (100 mg IV) before or with dextrose in any suspected alcoholic or malnourished patient. Vitamin B12 deficiency also causes neurological features (SCD) but not this acute ophthalmoplegic triad.
Mistake 6: Confusing collagen types (I bone, II cartilage, III reticular, IV basement membrane)
What students do: Mix up type II (cartilage) and type III (reticular); attribute Alport to type III instead of type IV.
Why it is wrong: Collagen MCQs test type-to-tissue matching AND disease associations (osteogenesis imperfecta, Ehlers-Danlos, Alport, Goodpasture, scurvy).
Correct approach: Match collagen type → tissue → disease.
| Type | Main tissues | Key diseases |
|---|
| Type I | Bone, skin, tendons, dentin, cornea, sclera, scar tissue (90-99 percent of body collagen) | Osteogenesis imperfecta (brittle bones, blue sclera, deafness, dentinogenesis imperfecta); low-quality scar in classical Ehlers-Danlos |
| Type II | Hyaline cartilage, articular cartilage, vitreous humor, nucleus pulposus of intervertebral disc | Spondyloepiphyseal dysplasia; Stickler syndrome; achondroplasia is FGFR3 mutation (not collagen per se) |
| Type III | Reticular fibers, skin (early wound healing), blood vessels, hollow viscera, granulation tissue | Ehlers-Danlos vascular type (type IV EDS — confusingly named; arterial and hollow organ rupture risk, short stature, translucent skin) |
| Type IV | Basement membranes (all epithelial basement membranes, glomerular basement membrane, lens capsule) | Alport syndrome (X-linked, alpha-5 chain mutation, progressive nephritis + sensorineural deafness + lenticonus); Goodpasture syndrome (anti-GBM antibodies targeting alpha-3 chain of type IV collagen; RPGN + pulmonary hemorrhage) |
| Type V | Hair, placenta, cell surfaces, minor component of bone and skin | Classical Ehlers-Danlos syndrome (joint hypermobility, skin hyperextensibility, atrophic scarring) |
| Type X | Hypertrophic cartilage, epiphyseal plate | Schmid metaphyseal chondrodysplasia |
Mnemonics:
- B-O-N-E = type I (Bone)
- "CAR two ilage" = type II (Cartilage)
- "Re-THREE-ticular" = type III (Reticular fibers)
- "base-FOUR-ment" = type IV (Basement membrane)
- "Hair-FIVE" = type V
Collagen synthesis requires:
- Vitamin C for prolyl and lysyl hydroxylation (scurvy = defective collagen = bleeding gums, corkscrew hairs)
- Copper for lysyl oxidase cross-linking (Menkes kinky hair disease, occipital horn syndrome)
- Vitamin B6 and zinc for amino acid metabolism
Example MCQ:
A 17-year-old boy presents with progressive sensorineural hearing loss, hematuria, and anterior lenticonus on slit-lamp examination. Renal biopsy shows thickened and split glomerular basement membrane with a 'basket-weave' appearance on electron microscopy. The collagen type defective in this condition is:
- (a) Type I
- (b) Type II
- (c) Type III
- (d) Type IV
Answer: (d). Alport syndrome is an X-linked (80 percent) or autosomal recessive disorder caused by mutations in the alpha-3, alpha-4, or alpha-5 chains of type IV collagen (basement membrane collagen). Clinical triad: progressive nephritis (RPGN-like), sensorineural deafness, and ocular defects (anterior lenticonus, dot-and-fleck retinopathy). Goodpasture syndrome also targets type IV collagen but via anti-GBM antibodies against the alpha-3 chain — Alport is genetic, Goodpasture is autoimmune.
Mistake 7: Wrong Fredrickson lipid disorder classification
What students do: Mix up Type IIa (familial hypercholesterolemia, LDL up) with Type IV (familial hypertriglyceridemia, VLDL up); forget Type III (dysbetalipoproteinemia) altogether.
Why it is wrong: Fredrickson classification is tested in pharmacology questions on statins, fibrates, and niacin.
Correct approach: Map Fredrickson type to lipoprotein, lipid profile, and clinical presentation.
| Fredrickson type | Elevated lipoprotein | Lipid profile | Genetics | Clinical features |
|---|
| Type I | Chylomicrons | Extreme triglycerides (above 1000 mg/dL); normal or mildly raised cholesterol | Lipoprotein lipase (LPL) deficiency; apoC-II deficiency; autosomal recessive | Eruptive xanthomas, lipemia retinalis, acute pancreatitis, hepatosplenomegaly; childhood onset |
| Type IIa | LDL | Raised total and LDL cholesterol; normal triglycerides | LDL receptor mutation (familial hypercholesterolemia); autosomal dominant | Tendon xanthomas (Achilles, finger extensors), xanthelasma, corneal arcus under age 50, premature atherosclerosis and CAD; MI in 30s-40s in homozygotes |
| Type IIb | LDL + VLDL | Raised cholesterol AND triglycerides | Familial combined hyperlipidemia; autosomal dominant | Premature CAD; xanthelasma; metabolic syndrome association |
| Type III | IDL (remnant) | Raised cholesterol AND triglycerides; broad beta band on electrophoresis | ApoE2/E2 homozygosity (defective remnant clearance); autosomal recessive | Palmar xanthomas (highly specific — pathognomonic), tubereruptive xanthomas, premature atherosclerosis |
| Type IV | VLDL | Raised triglycerides; normal or mildly raised cholesterol | Familial hypertriglyceridemia; polygenic | Eruptive xanthomas, pancreatitis, metabolic syndrome association |
| Type V | Chylomicrons + VLDL | Extreme triglycerides and cholesterol | ApoC-II deficiency; mixed inheritance | Eruptive xanthomas, lipemia retinalis, pancreatitis, hepatosplenomegaly |
Treatment pearls:
- Statin (HMG-CoA reductase inhibitor) — lowers LDL primarily; first-line for Type IIa and IIb
- Fibrates (fenofibrate, gemfibrozil) — lower triglycerides; first-line for Type I, IV, V and adjunct for III
- Niacin — lowers VLDL, LDL, and raises HDL; useful in mixed dyslipidemia; side effect flushing (aspirin pretreatment helps)
- PCSK9 inhibitors (evolocumab, alirocumab) — used in familial hypercholesterolemia refractory to statins
- Omega-3 fatty acids — adjunct for severe hypertriglyceridemia
Example MCQ:
A 32-year-old man with palmar xanthomas and tubereruptive xanthomas on elbows has total cholesterol 380 mg/dL, triglycerides 520 mg/dL, and lipoprotein electrophoresis showing a broad beta band. Genetic analysis reveals ApoE2/E2 homozygosity. The Fredrickson type and first-line treatment are:
- (a) Type I; gemfibrozil
- (b) Type IIa; high-intensity statin
- (c) Type III; fenofibrate or statin, dietary management
- (d) Type IV; fibrate monotherapy
Answer: (c). Palmar xanthomas are pathognomonic for Type III dysbetalipoproteinemia — remnant hyperlipoproteinemia from defective clearance of IDL and chylomicron remnants due to ApoE2/E2. Broad beta band on electrophoresis is diagnostic. Treatment is dietary modification, statins, or fibrates (or combination). Type I and V have extreme triglycerides (above 1000 mg/dL) with eruptive xanthomas and pancreatitis, not palmar xanthomas. Type IIa has tendon xanthomas with LDL elevation and normal triglycerides.
Mistake 8: Mixing up DNA repair defects (XP for NER, HNPCC for MMR, BRCA1/2 for homologous recombination)
What students do: Attribute xeroderma pigmentosum (XP) to mismatch repair instead of nucleotide excision repair.
Why it is wrong: DNA repair defect MCQs test pathway-to-disease matching and inheritance patterns — tested in pathology and genetics sections.
Correct approach: Match DNA repair pathway → disease → clinical features.
| Repair pathway | Function | Defective disease | Clinical features |
|---|
| Nucleotide excision repair (NER) | Repairs UV-induced pyrimidine dimers and bulky adducts | Xeroderma pigmentosum (XP) | Extreme photosensitivity, early-onset skin cancers (basal cell, squamous cell, melanoma), photophobia, neurological abnormalities; autosomal recessive |
| Mismatch repair (MMR) | Corrects DNA replication errors (mismatched bases, insertions, deletions) | Hereditary non-polyposis colorectal cancer (HNPCC / Lynch syndrome) | Early-onset colorectal cancer (right-sided), endometrial cancer, ovarian cancer, gastric cancer; MSH2, MLH1, MSH6, PMS2 mutations; autosomal dominant; microsatellite instability (MSI-high) |
| Homologous recombination (HR) | Repairs double-strand breaks using sister chromatid as template | BRCA1/BRCA2 mutations | Hereditary breast, ovarian, pancreatic, prostate cancer syndromes; autosomal dominant; sensitivity to PARP inhibitors (olaparib) |
| Non-homologous end joining (NHEJ) | Repairs double-strand breaks without template | Ataxia-telangiectasia (ATM gene) | Cerebellar ataxia, oculocutaneous telangiectasia, immunodeficiency, lymphoma risk, radiation sensitivity; autosomal recessive |
| Base excision repair (BER) | Repairs single damaged bases (oxidative damage) | MUTYH-associated polyposis (MAP) | Multiple colorectal adenomas, cancer risk; autosomal recessive |
| Fanconi anemia (FA) pathway | Repairs interstrand crosslinks | Fanconi anemia | Bone marrow failure, short stature, cafe-au-lait spots, thumb/radial anomalies, AML risk; autosomal recessive |
| Translesion synthesis | Bypasses DNA damage during replication | XP variant (POLH mutation) | Milder form of XP; photosensitivity; skin cancer risk |
Example MCQ:
A 6-year-old girl presents with severe photosensitivity, multiple basal cell carcinomas on sun-exposed skin, and a melanoma on the cheek. Parents are consanguineous. The most likely defective DNA repair pathway is:
- (a) Mismatch repair (MMR)
- (b) Nucleotide excision repair (NER)
- (c) Homologous recombination (HR)
- (d) Non-homologous end joining (NHEJ)
Answer: (b). Xeroderma pigmentosum is caused by defects in NER — the pathway that repairs UV-induced pyrimidine dimers. Patients develop severe photosensitivity and early-onset multiple skin cancers (BCC, SCC, melanoma) after minimal UV exposure. Autosomal recessive; consanguinity is a risk factor. MMR defect (HNPCC) causes colorectal and endometrial cancer. HR defect (BRCA1/2) causes breast and ovarian cancer. NHEJ defect (ataxia-telangiectasia) causes cerebellar ataxia and lymphoma risk.
Mistake 9: Confusing glycogen storage diseases (von Gierke, Pompe, Cori, Andersen, McArdle)
What students do: Mix up von Gierke (hepatic, G6Pase deficiency) with Pompe (cardiac, acid maltase deficiency) and McArdle (muscle, phosphorylase deficiency).
Why it is wrong: Glycogen storage diseases (GSD) are a high-yield topic. Each GSD has a characteristic enzyme defect, tissue involvement, and clinical triad.
Correct approach: Match GSD type → enzyme → tissue → clinical features.
| Type | Name | Enzyme defect | Tissue affected | Clinical features |
|---|
| Type I | Von Gierke | Glucose-6-phosphatase | Liver, kidney | Severe fasting hypoglycemia, hepatomegaly, lactic acidosis, hyperuricemia, hyperlipidemia, "doll-like" cherubic face; autosomal recessive |
| Type II | Pompe | Acid alpha-glucosidase (acid maltase) — lysosomal | Heart, skeletal muscle, liver | Cardiomegaly (hypertrophic), cardiorespiratory failure in infancy, muscle weakness, hypotonia ("floppy baby"); autosomal recessive; only GSD with lysosomal enzyme defect |
| Type III | Cori (Forbes) | Debranching enzyme (alpha-1,6-glucosidase) | Liver, muscle | Hepatomegaly, fasting hypoglycemia (milder than Type I), muscle weakness, hypotonia; autosomal recessive |
| Type IV | Andersen | Branching enzyme | Liver, muscle, heart | Cirrhosis, hepatomegaly, failure to thrive; autosomal recessive; poor prognosis |
| Type V | McArdle | Muscle glycogen phosphorylase (myophosphorylase) | Skeletal muscle only | Exercise intolerance, muscle cramps, myoglobinuria (dark urine after exercise), second-wind phenomenon; autosomal recessive |
| Type VI | Hers | Liver glycogen phosphorylase | Liver | Mild fasting hypoglycemia, hepatomegaly; autosomal recessive; good prognosis |
| Type VII | Tarui | Muscle phosphofructokinase (PFK-1) | Skeletal muscle, erythrocytes | Exercise intolerance, hemolytic anemia; autosomal recessive |
Key differentiators:
- Hepatic GSDs (hepatomegaly, fasting hypoglycemia): Types I, III, VI
- Muscle GSDs (exercise intolerance, cramps, myoglobinuria): Types V, VII
- Cardiac GSD: Type II (Pompe) — only GSD with cardiac involvement in infancy
- Most severe: Type II (Pompe, infantile form) and Type IV (Andersen) — cardiorespiratory failure or cirrhosis
- Second-wind phenomenon: Type V (McArdle) — exercise improves after initial pain because fatty acid oxidation takes over
Mnemonic: "Very Poor Carbohydrate metabolism" — Von Gierke (I), Pompe (II), Cori (III), Andersen (IV), McArdle (V), Hers (VI), Tarui (VII) — in order, or "VPCAMHT" as a sequence.
Example MCQ:
A 3-month-old infant presents with profound hypotonia ("floppy baby"), cardiomegaly on chest X-ray, and cardiorespiratory failure. Muscle biopsy shows lysosomal glycogen accumulation. The enzyme defect is:
- (a) Glucose-6-phosphatase
- (b) Acid alpha-glucosidase (acid maltase)
- (c) Muscle glycogen phosphorylase
- (d) Debranching enzyme
Answer: (b). Pompe disease (GSD II) is caused by lysosomal acid alpha-glucosidase (acid maltase) deficiency. It is the only glycogen storage disease with a lysosomal enzyme defect — glycogen accumulates in lysosomes of all tissues, but the heart and skeletal muscle are most severely affected. Infantile form presents with "floppy baby" phenotype, cardiomegaly, and cardiorespiratory failure — fatal without enzyme replacement therapy (alglucosidase alfa). Glucose-6-phosphatase deficiency = von Gierke (type I, hepatic); muscle phosphorylase = McArdle (type V, exercise intolerance); debranching enzyme = Cori (type III, hepatomegaly).
Mistake 10: Wrong inheritance pattern for common disorders (CF autosomal recessive, Huntington autosomal dominant, DMD X-linked recessive)
What students do: Confuse Duchenne with Becker; attribute Marfan to autosomal recessive; forget that cystic fibrosis is autosomal recessive.
Why it is wrong: Inheritance pattern is the simplest genetics question but carries high-yield pedigree analysis consequences.
Correct approach: Memorize inheritance patterns by disease category.
| Disease | Inheritance | Gene | Clinical features |
|---|
| Autosomal recessive | | | |
| Cystic fibrosis | AR | CFTR (chr 7; Delta-F508 commonest) | Recurrent lung infections, pancreatic insufficiency, male infertility (CBAVD), elevated sweat chloride |
| Sickle cell disease | AR | HBB (beta-globin; Glu6Val) | Hemolytic anemia, vaso-occlusive crises, autosplenectomy |
| Thalassemia major | AR | HBB or HBA | Transfusion-dependent anemia, iron overload |
| PKU | AR | PAH | Mental retardation if untreated; musty odor, eczema |
| Tay-Sachs | AR | HEXA | Cherry-red macula, neurodegeneration in Ashkenazi Jews |
| Wilson disease | AR | ATP7B | Hepatolenticular degeneration, Kayser-Fleischer rings |
| Hemochromatosis | AR | HFE | Iron overload, cirrhosis, diabetes, bronze skin |
| Glycogen storage diseases (most) | AR | — | Various tissue-specific presentations |
| Urea cycle disorders (except OTC) | AR | — | Hyperammonemia in newborns |
| Autosomal dominant | | | |
| Huntington disease | AD | HTT (CAG repeats) | Chorea, cognitive decline, psychiatric features; anticipation |
| Marfan syndrome | AD | FBN1 (fibrillin-1) | Tall stature, aortic dissection, lens dislocation, arachnodactyly |
| Neurofibromatosis type 1 | AD | NF1 (chr 17) | Cafe-au-lait spots, neurofibromas, Lisch nodules, optic glioma |
| Neurofibromatosis type 2 | AD | NF2 (chr 22) | Bilateral vestibular schwannomas, meningiomas |
| Familial hypercholesterolemia | AD | LDLR | Premature CAD, tendon xanthomas |
| Familial adenomatous polyposis | AD | APC | Hundreds of colonic polyps, CRC by age 40 |
| von Hippel-Lindau | AD | VHL | Hemangioblastomas, RCC, pheochromocytoma |
| Polycystic kidney disease (adult) | AD | PKD1, PKD2 | Bilateral kidney cysts, hepatic cysts, berry aneurysms |
| Osteogenesis imperfecta |
Key distinctions:
- DMD vs BMD: both are X-linked recessive dystrophin mutations; DMD has frameshift/large deletion → absent protein → severe; BMD has in-frame mutation → partially functional protein → mild
- Marfan is AUTOSOMAL DOMINANT (not recessive) — FBN1 mutation
- CF is AUTOSOMAL RECESSIVE (not X-linked despite male-predominant CBAVD)
- Huntington anticipation — CAG repeats expand in paternal transmission, earlier onset in successive generations
Example MCQ:
A 5-year-old boy presents with progressive proximal muscle weakness, difficulty climbing stairs, calf pseudohypertrophy, and a positive Gowers sign. Serum CK is 12,000 U/L. Muscle biopsy shows ABSENT dystrophin on Western blot. The inheritance pattern is:
- (a) Autosomal recessive
- (b) Autosomal dominant
- (c) X-linked recessive
- (d) Mitochondrial
Answer: (c). Duchenne muscular dystrophy is X-linked recessive — defect in the dystrophin gene (DMD, Xp21). Absent dystrophin (frameshift or large deletion) = DMD (severe, wheelchair by age 12); partially functional dystrophin (in-frame mutation) = Becker (milder). Male predominance, maternal carriers (asymptomatic or mild). Female carriers can show mild weakness due to skewed X-inactivation but typically are asymptomatic.
Comparison table: mistake vs correct approach
| Mistake | What students do | Correct approach |
|---|
| Enzyme kinetics | Confuse Vmax/Km effects of competitive vs non-competitive | Competitive: Vmax UNCHANGED, Km UP. Non-competitive: Vmax DOWN, Km UNCHANGED |
| Glycolysis rate-limiting | Call hexokinase the rate-limiting step | PFK-1 is rate-limiting, activated by F-2,6-BP, inhibited by ATP/citrate |
| Purely ketogenic amino acids | Include phenylalanine/tyrosine | Only leucine and lysine (the two Ls) |
| Urea cycle disorders | Confuse OTC and orotic aciduria | OTC: X-linked, high ammonia + high orotic acid + low citrulline. Orotic aciduria: AR, normal ammonia + high orotic acid + megaloblastic anemia |
| Vitamin deficiencies | Swap B12 neurological features with folate | B12: megaloblastic anemia + SCD. Folate: megaloblastic anemia WITHOUT neurological features |
| Collagen types | Mix II and III; attribute Alport to type III | I-bone, II-cartilage, III-reticular, IV-basement membrane (Alport, Goodpasture) |
| Fredrickson lipid types | Confuse Type IIa (LDL) and Type IV (VLDL) | IIa: LDL up (familial hypercholesterolemia, tendon xanthomas). IV: VLDL up (familial hypertriglyceridemia). III: palmar xanthomas pathognomonic (ApoE2/E2) |
| DNA repair defects | Attribute XP to MMR | XP = NER defect; HNPCC = MMR; BRCA = HR; ataxia-telangiectasia = NHEJ |
| Glycogen storage diseases | Confuse Pompe (lysosomal, cardiac) with other types | Pompe (II) = only lysosomal GSD, cardiomegaly in infancy; McArdle (V) = muscle only, second-wind |
| Inheritance patterns | Confuse CF, Marfan, DMD | CF = AR; Marfan = AD; DMD/BMD = XLR; Huntington = AD with anticipation |
Self-check checklist
Before NEET PG day, confirm you can answer each of these 7 yes/no checks:
- Can I draw the Lineweaver-Burk plot signatures of competitive, non-competitive, and uncompetitive inhibition?
- Can I list the rate-limiting enzymes of glycolysis, gluconeogenesis, TCA, fatty acid synthesis, fatty acid oxidation, cholesterol synthesis, and urea cycle?
- Can I name the only two purely ketogenic amino acids without looking?
- Can I distinguish OTC deficiency from orotic aciduria using ammonia, citrulline, and orotic acid levels?
- Can I match vitamin deficiencies to their signature clinical triads (B1-Wernicke triad, B3-pellagra 4 Ds, B12-SCD, C-scurvy, K-bleeding)?
- Can I match collagen types I-V to their tissues and associated diseases (osteogenesis imperfecta, EDS vascular, Alport, Goodpasture)?
- Can I classify the common genetic disorders by inheritance pattern (CF, sickle cell, Marfan, Huntington, DMD, Rett, MELAS)?
Frequently asked questions
How many biochemistry questions appear in NEET PG?
Biochemistry contributes 10-15 questions in NEET PG (2021-2024 pattern analysis) spanning enzyme kinetics (Km, Vmax, inhibition patterns), metabolism (glycolysis, TCA, fatty acid oxidation, urea cycle, gluconeogenesis), vitamins and deficiencies, hemoglobin and porphyrins, molecular biology (DNA replication, transcription, translation, repair), lipid metabolism (Fredrickson types), inborn errors (glycogen storage, amino acidopathies, lipidoses), and medical genetics (inheritance patterns, chromosomal disorders). While fewer in absolute count than Medicine or Pharmacology, biochemistry bleeds into Medicine (diabetes pathogenesis, lactic acidosis, liver function interpretation), Pharmacology (drug metabolism via CYP450), Pathology (hemoglobinopathies, leukemia molecular markers), and PSM (nutritional deficiencies). Getting the fundamentals right protects 20-25 marks across papers.
What is the commonest biochemistry mistake in NEET PG?
Confusing the rate-limiting and regulated enzymes across metabolic pathways is the costliest biochemistry mistake. Glycolysis rate-limiting enzyme is phosphofructokinase-1 (PFK-1), not hexokinase — hexokinase is the first enzyme but PFK-1 is the committed regulated step, allosterically inhibited by ATP and citrate and activated by fructose-2,6-bisphosphate and AMP. TCA cycle rate-limiting is isocitrate dehydrogenase (inhibited by ATP and NADH, activated by ADP). Gluconeogenesis rate-limiting is fructose-1,6-bisphosphatase-2 (FBP-2). Fatty acid synthesis rate-limiting is acetyl-CoA carboxylase. Fatty acid oxidation rate-limiting is CPT-1 (carnitine palmitoyltransferase-I, inhibited by malonyl-CoA). HMG-CoA reductase is rate-limiting for cholesterol synthesis (the statin target). Urea cycle rate-limiting is carbamoyl phosphate synthetase-I (CPS-I). Getting these wrong cascades into wrong answers on diabetes (liver PFK-2, muscle GLUT4), MSUD, OTC deficiency, and drug mechanism questions.
What is the difference between competitive and non-competitive enzyme inhibition?
Competitive inhibition: the inhibitor binds the active site competing with substrate; can be overcome by increasing substrate concentration. Effect on kinetics — Vmax UNCHANGED, Km INCREASED (apparent Km rises because you need more substrate to reach half-max velocity). Lineweaver-Burk plot — lines converge at the same y-intercept (same 1/Vmax) but different x-intercepts (different -1/Km). Classic example — methotrexate competitively inhibits dihydrofolate reductase; allopurinol competitively inhibits xanthine oxidase. Non-competitive inhibition: the inhibitor binds an allosteric site away from the active site; cannot be overcome by more substrate. Effect on kinetics — Vmax DECREASED, Km UNCHANGED (substrate still binds with same affinity but fewer functional enzymes available). Lineweaver-Burk plot — lines converge at the same x-intercept (same -1/Km) but different y-intercepts (different 1/Vmax). Mnemonic — "competitive competes, can be out-competed → same Vmax; non-competitive knocks enzyme out → lower Vmax." Uncompetitive inhibition (rare) — inhibitor binds only the enzyme-substrate complex, decreasing both Vmax AND Km proportionally.
Which amino acids are purely ketogenic?
Only two amino acids are purely ketogenic — leucine and lysine. They can only be converted to acetyl-CoA or acetoacetate (ketone body precursors) and cannot form glucose because they cannot enter gluconeogenesis above the oxaloacetate level. Purely glucogenic amino acids (13 total): alanine, arginine, asparagine, aspartate, cysteine, glutamate, glutamine, glycine, histidine, methionine, proline, serine, valine — these enter gluconeogenesis via pyruvate, oxaloacetate, alpha-ketoglutarate, succinyl-CoA, or fumarate. Both ketogenic and glucogenic (5 amino acids): isoleucine, phenylalanine, threonine, tryptophan, tyrosine — these can form both ketone bodies and glucose. Mnemonic — only leucine and lysine are purely ketogenic (remember "the two Ls"). NEET PG tests this by asking "which amino acid is purely ketogenic?" — the correct answer is leucine or lysine, not phenylalanine or tyrosine (which are both ketogenic AND glucogenic).
What are the key urea cycle disorders?
The urea cycle has five enzymes; deficiency of any enzyme causes hyperammonemia with neurotoxicity. Most common: ornithine transcarbamylase (OTC) deficiency — the only X-linked urea cycle disorder (all others autosomal recessive). OTC deficiency presents with hyperammonemia, low citrulline (OTC is the step that makes citrulline), and high urinary orotic acid (carbamoyl phosphate substrate accumulates and spills into pyrimidine synthesis → orotic aciduria). Orotic aciduria (pyrimidine synthesis defect) — distinguish from OTC deficiency — presents with megaloblastic anemia and failure to thrive; urinary orotic acid is high but ammonia is NORMAL and citrulline is normal (cause is UMP synthase deficiency, not urea cycle). Carbamoyl phosphate synthetase-I (CPS-I) deficiency — rate-limiting enzyme of urea cycle — severe hyperammonemia, low citrulline, normal orotic acid (no orotate accumulation because substrate is carbamoyl phosphate, not its precursors). Argininosuccinate synthetase deficiency (citrullinemia) — high citrulline, high ammonia, low argininosuccinate. Arginase deficiency — late presentation with progressive spastic paraparesis, high arginine.
How do the major vitamin deficiencies present clinically?
Eight high-yield vitamin deficiencies with system-level presentations. Vitamin A (retinol) — night blindness (early), xerophthalmia, keratomalacia, Bitot spots; respiratory infections in children. Vitamin B1 (thiamine) — dry beriberi (peripheral neuropathy), wet beriberi (high-output heart failure), Wernicke encephalopathy (confusion, ophthalmoplegia, ataxia triad), Korsakoff psychosis (anterograde amnesia with confabulation). Vitamin B2 (riboflavin) — angular cheilitis, glossitis, seborrheic dermatitis, corneal vascularization. Vitamin B3 (niacin) — pellagra with the 4 Ds (dermatitis photosensitive in sun-exposed areas, diarrhea, dementia, death); seen in corn-based diets and Hartnup disease. Vitamin B12 (cobalamin) — megaloblastic anemia, glossitis, subacute combined degeneration of spinal cord (posterior columns + lateral corticospinal tract); pernicious anemia is the classic cause. Folate — megaloblastic anemia WITHOUT neurological features (key distinction from B12); neural tube defects if deficient in pregnancy. Vitamin C (ascorbate) — scurvy with bleeding gums, perifollicular hemorrhages, corkscrew hairs, poor wound healing; collagen hydroxylation defect. Vitamin K — bleeding (PT and INR prolonged, APTT prolonged in severe deficiency); newborn hemorrhagic disease; warfarin reversal with vitamin K.
What are the classic collagen types and their disease associations?
Five main collagen types are tested in NEET PG with specific disease associations. Type I collagen — bone, skin, tendons, dentin, cornea, sclera, scar tissue (99 percent of body collagen); defective in osteogenesis imperfecta (brittle bones, blue sclera, deafness, dentinogenesis imperfecta). Type II collagen — hyaline cartilage (articular), vitreous humor, nucleus pulposus of intervertebral disc; defective in achondroplasia (FGFR3 mutation, not collagen but FGF receptor), SED (spondyloepiphyseal dysplasia). Type III collagen — reticular fibers, skin, blood vessels, granulation tissue, internal organs; defective in Ehlers-Danlos syndrome vascular type (type IV EDS with arterial and hollow-organ rupture risk). Type IV collagen — basement membrane, glomerular basement membrane, lens capsule; defective in Alport syndrome (X-linked, progressive nephritis + sensorineural deafness + lenticonus) and Goodpasture syndrome (anti-GBM antibodies targeting alpha-3 chain of type IV collagen, causing RPGN + pulmonary hemorrhage). Type V collagen — hair, placenta; defective in classical Ehlers-Danlos syndrome. Mnemonic — B-O-N-E (I), C-A-R-twoilage (II), Re-THREE-ticular (III), base-FOUR-ment (IV). Collagen synthesis requires vitamin C for hydroxylation of proline and lysine — vitamin C deficiency causes scurvy.
How is biochemistry tested in NEET PG?
NBE tests biochemistry through six patterns: enzyme kinetics (Km, Vmax, Lineweaver-Burk plots, competitive vs non-competitive inhibition), metabolic pathway rate-limiting enzymes (PFK-1 for glycolysis, HMG-CoA reductase for cholesterol, CPT-1 for fatty acid oxidation), inborn errors of metabolism (PKU, MSUD, alkaptonuria, urea cycle disorders with ammonia and orotic acid levels, glycogen storage diseases by enzyme defect), vitamin deficiency clinical matching (B1-Wernicke, B3-pellagra, B12-SCD, C-scurvy, K-bleeding), collagen type to disease association (I-osteogenesis imperfecta, III-vascular EDS, IV-Alport/Goodpasture), and inheritance pattern matching (CF autosomal recessive, Huntington autosomal dominant, DMD X-linked recessive, Duchenne vs Becker distinction, mitochondrial maternal inheritance). Expect 2-3 biochemistry questions per NEET PG paper in the pre-clinical section. Biochemistry also surfaces in Medicine via metabolic acidosis patterns and in Pathology via tumor markers.
This content is for educational purposes for NEET PG exam preparation. It is not a substitute for professional medical advice, diagnosis, or treatment. Clinical information has been reviewed by qualified medical professionals.
Sources and references
- Lehninger AL, Nelson DL, Cox MM, Principles of Biochemistry, 8th Edition (W.H. Freeman, 2021) — canonical biochemistry textbook covering enzyme kinetics, metabolism, and molecular biology in depth for NEET PG preparation.
- Harper's Illustrated Biochemistry, 32nd Edition (McGraw-Hill, 2022) — Indian-medical-school-standard reference with rate-limiting enzymes, vitamin deficiencies, and inborn errors of metabolism in exam-relevant depth.
- DM Vasudevan, Textbook of Biochemistry for Medical Students, 9th Edition (Jaypee, 2019) — widely used Indian biochemistry text with clinical case vignettes and NEET PG-pattern exam questions.
Strengthen your biochemistry pattern recognition by pairing this mistake guide with the NEET PG biochemistry high-yield topics, the companion common physiology mistakes guide, and the biochemistry subject page. Ready for unlimited AI-powered MCQs with detailed explanations? Explore NEETPGAI Pro.
For a structured final-month biochemistry plan, try the AI-generated study plan — it sequences enzyme kinetics, metabolism, and inborn errors according to your remaining weeks.
Written by: NEETPGAI Editorial Team
Reviewed by: Pending SME Review
Last reviewed: March 2026
This article is reviewed by qualified medical professionals for clinical accuracy and exam relevance. For corrections or updates, contact the editorial team.
